5423-54-1Relevant articles and documents
A fluorescent material, preparation method and application
-
Paragraph 0062; 0064; 0066-0067, (2019/07/01)
The invention discloses a kind of fluorescent material, preparation method and application, wherein the fluorescent material of the molecular structure of the general formula as follows: R1 - R6 are each independently selected from H atom, deuterium atoms, to the electronic group or pulling in the electronic group a; and R1 - R6 at least one electron-donating groups, at least one of the is dragging the electronic group. The present invention provides fluorescent material, with twisted of - A D (Donor) (Acceptor) structure, at the same time with a heat-activated delay fluorescent and aggregation induced characteristic, not only can realize 100% internal quantum efficiency, but also can reduce the aggregation caused by the luminescence quenching process. These material is used as the doping and-layer films of the organic electroluminescent device in the light-emitting layer of the light-emitting object, its efficiency can be comparable with the phosphorescence, and avoid the problems of the prior phosphorescent material usually to use heavy metal is the iridium, platinum and the problem of expensive heavy metal, the cost is reduced.
Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action
Selakovi?, ?ivota,Tran, Julie P.,Kota, Krishna P.,Lazi?, Marija,Retterer, Cary,Besh, Robert,Panchal, Rekha G.,Soloveva, Veronica,Sean, Vantongreen A.,Jay, Wells B.,Pavi?, Aleksandar,Verbi?, Tatjana,Vasiljevi?, Branka,Kuehl, Kathleen,Duplantier, Allen J.,Bavari, Sina,Mudhasani, Rajini,?olaja, Bogdan A.
supporting information, p. 32 - 50 (2018/11/21)
Ebola virus (EBOV) causes a deadly hemorrhagic fever in humans and non-human primates. There is currently no FDA-approved vaccine or medication to counter this disease. Here, we report on the design, synthesis and anti-viral activities of two classes of compounds which show high potency against EBOV in both in vitro cell culture assays and in vivo mouse models Ebola viral disease. These compounds incorporate the structural features of cationic amphiphilic drugs (CAD), i.e they possess both a hydrophobic domain and a hydrophilic domain consisting of an ionizable amine functional group. These structural features enable easily diffusion into cells but once inside an acidic compartment their amine groups became protonated, ionized and remain trapped inside the acidic compartments such as late endosomes and lysosomes. These compounds, by virtue of their lysomotrophic functions, blocked EBOV entry. However, unlike other drugs containing a CAD moiety including chloroquine and amodiaquine, compounds reported in this study display faster kinetics of accumulation in the lysosomes, robust expansion of late endosome/lysosomes, relatively more potent suppression of lysosome fusion with other vesicular compartments and inhibition of cathepsins activities, all of which play a vital role in anti-EBOV activity. Furthermore, the diazachrysene 2 (ZSML08) that showed most potent activity against EBOV in in vitro cell culture assays also showed significant survival benefit with 100% protection in mouse models of Ebola virus disease, at a low dose of 10 mg/kg/day. Lastly, toxicity studies in vivo using zebrafish models suggest no developmental defects or toxicity associated with these compounds. Overall, these studies describe two new pharmacophores that by virtue of being potent lysosomotrophs, display potent anti-EBOV activities both in vitro and in vivo animal models of EBOV disease.
Discovery of an Inhibitor of the Proteasome Subunit Rpn11
Perez, Christian,Li, Jing,Parlati, Francesco,Rouffet, Matthieu,Yuyong,Mackinnon, Andrew L.,Chou, Tsui-Fen,Deshaies, Raymond J.,Cohen, Seth M.
, p. 1343 - 1361 (2017/03/08)
The proteasome plays a crucial role in degradation of normal proteins that happen to be constitutively or inducibly unstable, and in this capacity it plays a regulatory role. Additionally, it degrades abnormal/damaged/mutant/misfolded proteins, which serves a quality-control function. Inhibitors of the proteasome have been validated in the treatment of multiple myeloma, with several FDA-approved therapeutics. Rpn11 is a Zn2+-dependent metalloisopeptidase that hydrolyzes ubiquitin from tagged proteins that are trafficked to the proteasome for degradation. A fragment-based drug discovery (FBDD) approach was utilized to identify fragments with activity against Rpn11. Screening of a library of metal-binding pharmacophores (MBPs) revealed that 8-thioquinoline (8TQ, IC50 value ～2.5 μM) displayed strong inhibition of Rpn11. Further synthetic elaboration of 8TQ yielded a small molecule compound (35, IC50 value ～400 nM) that is a potent and selective inhibitor of Rpn11 that blocks proliferation of tumor cells in culture.
